227963-15-7
227963-15-7 結(jié)構(gòu)式
基本信息
L-000845704
HGFOOLONGOBCMP-IBGZPJMESA-N
3-Pyridinepropanoic acid, 6-methoxy-β-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1-imidazolidinyl]-, (βS)-
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/02/08 | HY-15102 | 化合物 T16085 MK-0429 | 227963-15-7 | 1 mg | 2045元 |
| 2025/02/08 | HY-15102 | 化合物 T16085 MK-0429 | 227963-15-7 | 5mg | 4500元 |
| 2025/02/08 | HY-15102 | 化合物 T16085 MK-0429 | 227963-15-7 | 10mM * 1mLin DMSO | 4950元 |
常見問題列表
|
αvβ1 1.6 nM (IC 50 , inhibition of fibronectin-binding ) |
αvβ3 2.8 nM (IC 50 , inhibition of vitronectin-binding) |
αvβ5 0.1 nM (IC 50 , inhibition of vitronectin-binding) |
αvβ6 0.7 nM (IC 50 , inhibition of LAP-binding) |
αvβ8 0.5 nM (IC 50 , inhibition of LAP-binding) |
α5β1 12.2 nM (IC 50 , inhibition of fibronectin-binding) |
MK-0429 (100 or 300 mg/kg, p.o., twice daily b.i.d., 2 weeks) reduces metastatic tumor colony formation and area in the lungs. MK-0429 is safe and efficacious in significantly decreasing melanoma metastasis in the lungs.
| Animal Model: | B6D2F1 hybrid female mice |
| Dosage: | 100 or 300 mg/kg |
| Administration: | P.o., twice daily (b.i.d.), 2 weeks |
| Result: | MK-0429 at 100 and 300 mg/kg reduced the number of metastatic tumor colonies by 64 and 57%, respectively, and the high dose also reduced the tumor area by 60% as compared to the vehicle [2] . |